首页> 外文期刊>Seizure: the journal of the British Epilepsy Association >Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine
【24h】

Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine

机译:新一代钠阻滞剂抗癫痫药的神经系统不良事件。醋酸埃斯卡西平,拉考酰胺和奥卡西平的随机,双盲研究的荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose Analysis of overall tolerability and neurological adverse effects (AEs) of eslicarbazepine acetate (ESL), lacosamide (LCM) and oxcarbazepine (OXC) from double-blind, placebo-controlled trials. Indirect comparisons of patients withdrawing because of AEs, and the incidence of some vestibulocerebellar AEs between these three antiepileptic dugs (AEDs). Methods We searched MEDLINE for all randomized, double-blind, placebo-controlled trials investigating therapeutic effects of fixed oral doses of ESL, LCM and OXC in patients with drug resistant epilepsy. Withdrawal rate due to AEs, percentages of patients with serious AEs, and the proportion of patients experiencing any neurological AE, nausea and vomiting were assessed for their association with the experimental drug. Analyses were performed between recommended daily doses of each AED according to the approved summary of product characteristics (SPC). Risk differences were used to evaluate the association of any AE [99% confidence intervals (CIs)] or study withdrawals because of AEs (95% CIs) with the experimental drug. Indirect comparisons between withdrawal rate and AEs dizziness, coordination abnormal/ataxia and diplopia were estimated according to network meta-analysis (Net-MA). Results Eight randomized, placebo-controlled, double-blind trials (4 with ESL, 3 with LCM, and 1 with OXC) were included in our analysis. At high doses (OXC 1200 mg, ESL 1200 mg and LCM 400 mg) there was an increased risk of AE-related study withdrawals compared to placebo for all drugs. Several AEs were associated with the experimental drug. Both number and frequency of AEs were dose-related. At high recommended doses, patients treated with OXC withdrew from the experimental treatment significantly more frequently than patients treated with ESL and LCM. Furthermore, the AEs coordination abnormal/ataxia and diplopia were significantly more frequently observed in patients treated with OXC compared to patients treated with LCM and ESL. Conclusions The overall tolerability of AEDs and the incidence of several neurological AEs were clearly dose-dependent. Indirect comparisons between these AEDs, taking into account dose-effect, showed that OXC may be associated with more frequent neurological AEs than LCM and ESL.
机译:目的从双盲,安慰剂对照试验中分析乙酸依卡西平(ESL),拉考酰胺(LCM)和奥卡西平(OXC)的总体耐受性和神经系统不良反应(AE)。这三种抗癫痫药(AED)之间因AE退出的患者以及某些前庭小脑AE发生率的间接比较。方法我们在MEDLINE中搜索了所有随机,双盲,安慰剂对照试验,研究了口服固定剂量的ESL,LCM和OXC对耐药性癫痫患者的治疗效果。评估由于不良事件引起的戒断率,严重不良事件患者的百分比以及经历任何神经系统不良事件,恶心和呕吐的患者比例与实验药物的关系。根据批准的产品特征摘要(SPC),在每种AED的建议每日剂量之间进行分析。风险差异用于评估任何不良事件[99%置信区间(CIs)]的关联性,或研究由于不良事件(95%CIs)而与试验药物相关的戒断。根据网络荟萃分析(Net-MA)估算了戒断率与AEs头晕,协调异常/共济失调和复视之间的间接比较。结果我们的分析包括八项随机,安慰剂对照,双盲试验(ESL 4例,LCM 3例,OXC 1例)。与所有安慰剂相比,在高剂量(OXC 1200 mg,ESL 1200 mg和LCM 400 mg)下,与AE相关的研究退出的风险增加。几种AE与实验药物有关。不良事件的数量和频率均与剂量有关。在高推荐剂量下,用OXC治疗的患者退出实验治疗的频率明显高于用ESL和LCM治疗的患者。此外,与接受LCM和ESL的患者相比,接受OXC的患者出现AEs协调异常/共济失调和复视的频率更高。结论AED的总体耐受性和几种神经系统AE的发生明显与剂量有关。考虑到剂量效应,这些AED之间的间接比较表明,与LCM和ESL相比,OXC可能与更频繁的神经学AE相关。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号